



EPEIUS BIOTECHNOLOGIES CORPORATION RECEIVES \$400,000 GRANT TO SUPPORT GENE THERAPY TRIALS FOR PANCREATIC CANCER.

SAN MARINO, California, June 19, 2006 – Epeius Biotechnologies Corporation announced today that the Company has been awarded a \$400,000 grant by the Lazarex Cancer Foundation to expand and support ongoing cancer gene therapy clinical trials for advanced and metastatic pancreatic cancer. Regin-G™ is the world's first targeted injectable gene therapy vector to be approved for use in clinical trials in the USA and abroad. When injected intravenously, Regin-G™ seeks out and destroys metastatic cancer, without the systemic toxicity generally associated with chemotherapy. Regin-G™ recently gained Orphan Drug status as an effective treatment for pancreatic cancer in the United States, and is currently available in clinical trials in Rochester MN. In a statement to the press, Ms. Dana Dornsife, President of the Lazarex Cancer Foundation said: "We are pleased to provide Epeius Biotechnologies Corporation the funds needed to expedite the development of such promising genetic medicines, which - by improving both the survival and the quality of life – provide cancer patients with *more quality time.*"

CLINICAL TRIALS: Dr. Erlinda M. Gordon
Medical Director

MEDIA CONTACT: Dr. Frederick L. Hall
President and CEO

Phone: 626-441-6695

FAX: 626-441-6692

Email: info@epeiusbiotech.com

Website: <http://www.epeiusbiotech.com>